Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Edoxaban Versus Dalteparin in Cancer-Associated VTE – JTH
Nick van Es/First Author of The Article/LinkedIn
Feb 20, 2026, 09:14

Edoxaban Versus Dalteparin in Cancer-Associated VTE – JTH

Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Nick van Es et al, adding:

”The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE Cancer trial

Novel win ratio analysis comparing edoxaban versus dalteparin in cancer-associated VTE reveals no significant difference between treatments when evaluating hierarchically prioritized outcomes including mortality, recurrent events, and bleeding complications.”

Title: The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial

Authors: Nick van Es, Luuk Scheres., Kristen Sanfilippo, Harry Buller, Marc Carrier, Marcello Di Nisio, Michael A. Grosso, Renato D. Lopes, William McIntyre, Björn Redfors, Annelise Segers, Peter Verhamme, Jeff Weitz, Patrick Bossuyt, Deborah Siegal

Read the Full Article on JTH

Edoxaban Versus Dalteparin in Cancer-Associated VTE - JTH

Stay updated on all scientific advances with Hemostasis Today.

Annelise Segers Björn Redfors cancer CAT dalteparin Deborah Siegal edoxaban Harry Büller Health Hematology Hemostasis Hemostasis News Hemostasis Today Hokusai Jeff Weitz JTH Kristen Sanfilippo Luuk Scheres. Marc Carrier Marcello Di Nisio Medicine Michael A. Grosso Nick van Es OncoDaily Patrick Bossuyt Peter Verhamme Renato D. Lopes thrombosis VTE William McIntyre
NewsFeed